Psychedelics company Wellbeing Digital Sciences Inc. (OTC: KONEF)’s subsidiary KGK Science Inc. has entered into a research services agreement with Canadian-based biotech Nova Mentis Life Science Corp. (OTC: NMLSF) for a first-of-its-kind Phase 2 clinical trial on psilocybin microdoses’ efficacy to improve behavioral and cognitive symptoms associated with the genetic disorder Fragile X syndrome (FXS.) FXS is a genetic condition that causes a range of developmental problems including learning disabilities and cognitive impairment.

The deal foresees KGK being in charge of providing …

Full story available on Benzinga.com